Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (690)	6/26/2003 6:33:34 AM
From: nigel bates	Read Replies (1) \| Respond to of 2240

Northwest Biotherapeutics Identifies CXCR-4 Clinical Antibodies That Inhibit Tumor Cell Division and Metastasis Thursday June 26, 5:49 am ET BOTHELL, Wash., June 26 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT - News) announced yesterday the completion of its in vitro pre-clinical assessment of a battery of proprietary monoclonal antibodies directed against the cancer associated target CXCR-4. Two of the studied antibodies inhibited tumor cell division and exhibited other anti-cancer properties. NWBT scientists were the first to discover that CXCR-4 is over-expressed in cancer. The original findings showed CXCR-4 detectable in Glioblastoma and Breast cancer tissue but not measurable in normal counterpart tissue. These findings formed the basis for Company patent applications filed in early 1998. Subsequently, CXCR-4 has been identified in approximately 75% of all diagnosed cancers. In recently completed laboratory studies, Company scientists found that the two antibodies inhibiting tumor growth also induce cell death, or apoptosis, in several different human cancer cell lines. In addition, these antibodies were found to block the movement or chemotaxis and invasion of cancer cells through other tissue in commonly used tests of metastasis. Dr. Eric Holmes, the Company's Vice President of Biomedical R&D, stated, "Our findings are consistent with publications from other laboratories reporting that certain antibodies to CXCR-4 can prevent human tumor cell growth and metastasis in different animal model systems. Several of these studies also demonstrated that mice treated with antibodies to CXCR-4 were cured of their cancer." Dr. Holmes indicated that the Company is initiating the next phase of its evaluation intended to identify the single antibody with the greatest potential clinical utility. "Once we identify which of the two antibodies represents the best therapeutic product candidate, we can have it humanized for use in potential future clinical trials," Holmes stated.